Everolimus slows disease progression in advanced papillary kidney cancer ... RxPG NEWS By ECCO-the European CanCer Organisation, [RxPG] The first Phase II study to investigate the use of the anti-cancer drug, everolimus, for the initial treatment of advanced papillary kidney cancer has shown that it is successful in slowing or preventing ... |
